Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Gastrointestinal Motility Disorders

Gastrointestinal Motility Disorders

Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...

Other Disorders of Digestive System

Other Disorders of Digestive System

The gastrointestinal tract is susceptible to various disorders. If the lower esophageal sphincter is damaged, stomach acid can flow back into the esophagus, causing irritation and inflammation of the lining. This condition is called gastroesophageal reflux disease (known as heartburn) and may cause chest pain and difficulty swallowing. In the stomach, prolonged use of nonsteroidal anti-inflammatory drugs like aspirin, chronic alcohol consumption, bacterial infections such as Helicobacter...

Chronic Bowel Disorders: Introduction

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...

Irritable Bowel Syndrome

Irritable Bowel Syndrome

DefinitionIrritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by recurrent combinations of abdominal pain, bloating, diarrhea, or constipation.Pathophysiology of irritable bowel syndromeIts pathophysiology is multifactorial, involving disturbances in motility, sensory processing, microbial balance, barrier integrity, and gut–brain communication. These mechanisms interact to produce symptoms that vary across IBS subtypes.Altered Motility PatternsDisordered...

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Definitive single-fraction ablative radiotherapy for early-stage breast cancer: DESERT-I trial - a dose-escalation study protocol.

Radiation oncology (London, England)·2026

Same author

Palbociclib, Trastuzumab, and Endocrine Therapy in Pretreated HER2-Positive and PAM50 Luminal Advanced Breast Cancer: Randomized Phase II, SOLTI-1303 PATRICIA Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025

Same author

Economic burden of eosinophilic esophagitis in the first year after diagnosis in Spain: A direct medical cost analysis.

The European journal of health economics : HEPAC : health economics in prevention and care·2025

Same author

Effectiveness and Safety of First-Line Non-Bismuth Quadruple Concomitant Therapy Versus Single-Capsule Bismuth Quadruple Therapy.

Alimentary pharmacology & therapeutics·2025

Same author

Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: PALMIRA Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

Same author

Clinical Trial: Safety and Efficacy of a Novel Oesophageal Delivery System for Topical Corticosteroids Versus Placebo in the Treatment of Eosinophilic Oesophagitis.

Alimentary pharmacology & therapeutics·2024

Search research articles

Related Experiment Video

Updated: Jun 23, 2026

Using An In Vitro Tissue Perfusion System to Detect the Functional Activities of Isolated Intestinal Tubes in Real Time

Using An In Vitro Tissue Perfusion System to Detect the Functional Activities of Isolated Intestinal Tubes in Real Time

Published on: July 26, 2024

[Functional and motor gastrointestinal disorders].

Fermín Mearin¹, Antonia Perelló, Agustín Balboa

¹Servicio de Aparato Digestive, Instituto de Trastornos Funcionales y Motores Digestivos, Centro Medico Teknon, Barcelona, España. mearin@dr.teknon.es

Gastroenterologia Y Hepatologia

|May 13, 2009

Summary

This summary is machine-generated.

Advances in functional gastrointestinal (GI) disorders were presented in 2008, focusing on new physiopathology insights and therapeutic agents for conditions like functional dyspepsia and irritable bowel syndrome.

More Related Videos

Gastrointestinal Motility Monitor (GIMM)

Gastrointestinal Motility Monitor (GIMM)

Published on: December 1, 2010

Related Experiment Videos

Last Updated: Jun 23, 2026

Using An In Vitro Tissue Perfusion System to Detect the Functional Activities of Isolated Intestinal Tubes in Real Time

Using An In Vitro Tissue Perfusion System to Detect the Functional Activities of Isolated Intestinal Tubes in Real Time

Published on: July 26, 2024

Gastrointestinal Motility Monitor (GIMM)

Gastrointestinal Motility Monitor (GIMM)

Published on: December 1, 2010

Area of Science:

Gastroenterology
Physiology
Pharmacology

Context:

Functional gastrointestinal (GI) and motility disorders are common, leading to numerous consultations.
The American Gastroenterological Association's 2008 meeting highlighted key research in this field.

Purpose:

To summarize significant studies presented at the 2008 American Gastroenterological Association meeting.
To provide an overview of advancements in the understanding and treatment of functional GI disorders.

Summary:

New data on the physiopathology of functional GI disorders include neuromodulators, microinflammation, microbiota alterations, and psychological factors.
Therapeutic advancements were discussed for functional dyspepsia (acotiamide), irritable bowel syndrome (mesalazine, rifaximin, probiotics, lubiprostone), constipation (prucalopride, linaclotide, biofeedback), and gastroparesis.
Studies evaluated diagnostic criteria applicability and presented novel treatment strategies.

Impact:

The 2008 findings offer valuable information for physicians managing functional GI and motor disorders.
These advancements contribute to improved patient selection and symptom control for various GI conditions.